Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Option Care (OPCH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Option Care (OPCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 3.55% and 5.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips (PHG) Drives Healthcare Prospects With Enhanced Dataset
by Zacks Equity Research
Philips (PHG) announces its expansion with MIT IMES, which will help researchers and educators access a new critical care dataset.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Humana (HUM) This Year?
by Zacks Equity Research
Here is how Humana (HUM) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Philips (PHG) Inks 7-Year Partnership With Northwell Health
by Zacks Equity Research
Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.
Philips (PHG) Drives Health Care Prospects With New Solutions
by Zacks Equity Research
Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.
Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group
by Zacks Equity Research
Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.
Here's Why You Should Retain HCA Healthcare (HCA) Stock Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.
4 Promising Stocks From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Is Addus HomeCare (ADUS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and Alcon (ALC) have performed compared to their sector so far this year.
What Makes Addus HomeCare (ADUS) a New Buy Stock
by Zacks Equity Research
Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 14.43% and 0.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: What to Expect
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant
by Zacks Equity Research
Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.
Addus HomeCare (ADUS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.08% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.